Investigating Resistance in ROS1+ Lung Cancer

Robert C. Doebele, MD, PhD

Robert C. Doebele, MD, PhD, discusses resistance in patients with ROS1-positive lung cancer.

Robert C. Doebele, MD, PhD, associate professor at the University of Colorado, discusses resistance in patients withROS1-positive lung cancer.

According to Doebele, studies are still early in this patient population, but 2 have been published so far. Both showed thatROS1mutations can occur, but data published from the University of Colorado, showed a rate of about 10%, while the study from Massachusetts General Hospital showed about 50%.

While these results are very different, both studies were relatively small. Doebele believes it might be around 30%, as withALK+lung cancer. Drugs need to be developed to overcome kinase domain mutations in ROS1, but first investigators must identify what those resistance mutations are and the other type of resistance mechanisms in ROS1+